Weak results for weekly albiglutide

A new once-weekly GLP-1 receptor agonist, albiglutide, is not as effective as the current daily injectable drugs in reducing glycaemia in patients with type 2 diabetes, a clinical trial has shown.

While the new drug was more tolerable in terms of GI adverse effects, once-weekly injections of albiglutide were inferior to daily injections of liraglutide in reducing HbA1c levels, according to a multicentre trial that included nine Australian centres.

Published in the Lancet Diabetes & Endocrinology, results from the 32-week